GT20029 & KX826 Major Updates from Kintor.
    Research/Science 11/30/2024

    At a glance
    In this research update post, the primary subjects mentioned are
    💧 KX826 (topical) 0.5% 2x daily 52 weeks
    the tone is mixed with 10% increase in hair count results.

    Other terms

    KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.
    View this post in the Community →

    Similar Community Posts Join

    5 / 174 results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community KX-826 Pyrilutamide1% coming soon

      in Update  152 upvotes 3 months ago
      KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

      community Kintor’s GT20029 Phase 1 success

      in Update  73 upvotes 1 year ago
      Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

    Related Research

    5 / 5 results